Morgan Stanley Sees Attractive Risk/Reward for Medtronic

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $73.00 price target on

. In the report, Morgan Stanley noted, “The pipeline is driving growth and stronger EM and improving margins should bolster fundamentals through the year. Despite noise on inversion, we believe the deal will go through. Growth and shareholder returns are going higher and at 13x pro forma cash EPS, we see an attractive risk reward.” Medtronic closed on Tuesday at $64.01.